Artimplant publishes Interim Report January-March 2011 on May 4, 2011 at approximately 3 PM (GMT+1)

Artimplant publishes Interim Report January-March 2011 on May 4, 2011 at approximately 3 PM (GMT+1). The Interim Report is presented at the Annual Meeting of Stockholders on May 4, 2011 at 5 PM (GMT+1). No conference call will be held regarding this report.

CEO Hans Rosén and CFO Kjell Thörnbring present the Interim Report at the Annual Meeting of Stockholders on May 4, 2011 at 5 PM (GMT+1). No conference call will be held, but the CEO's presentation at the Annual Meeting of Stockholders and the presentation of the Interim Report January-March, 2011 will be published at the Company's home page after the Annual Meeting of Stockholders. http://www.artimplant.com/investors-media/presentations.html

The presentations will be in Swedish.

For further information, please contact: Hans Rosén, CEO, phone +46 (0)31-746 56 00, +46 (0)708 58 34 70, hans.rosen@artimplant.com Kjell Thörnbring, CFO, phone +46 (0)31-746 56 54, +46 (0)703 01 68 54, kjell.thornbring@artimplant.com Web site: www.artimplant.com

Artimplant

Artimplant’s mission is to restore the health of patients by offering medical professionals degradable implants that help the body to heal. Artimplant is a medical device company that restores health through the development, production and marketing of degradable implants that regenerate body functions and improve quality of life. Our products are made from Artelon®, a biomaterial developed by the Company. Artimplant's implants are used for the treatment of osteoarthritis and the reinforcement of weakened soft tissue. The Company's products are sold through licensees and own sales under the Artimplant brand take place through agents and distributors. Artimplant is a public company listed on the NASDAQ OMX Stockholm Exchange in the Small Cap segment and in the Healthcare sector.

Forward-looking statements

This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.

This is information which Artimplant shall make public pursuant to the Swedish Financial Instruments Act and the Swedish Securities Exchange and Clearing Operations Act and/or stock market agreements. Information was made available for publication on May 2 2011 at 14:00 am (CET).